English

www.astrazeneca.com

more

Thursday, Jun 27

01

Tagrisso with the addition of chemotherapy approved in China as 1st-line treatment for patients with EGFR-mutated advanced lung cancer

www.astrazeneca.com

Tuesday, Jun 25

00

Tagrisso with the addition of chemotherapy approved in Japan as new 1st-line treatment for patients with EGFR-mutated advanced lung cancer

www.astrazeneca.com

Update on ADJUVANT BR.31 Phase III trial of Imfinzi in non-small cell lung cancer

www.astrazeneca.com

Imfinzi demonstrated statistically significant and clinically meaningful improvement in event-free survival and overall survival for muscle-invasive bladder cancer in NIAGARA Phase III trial

www.astrazeneca.com

Thursday, Jun 20

21

Truqap plus Faslodex approved in the EU for patients with advanced ER-positive breast cancer

www.astrazeneca.com

Tuesday, Jun 18

19

Update on the CAPItello-290 Phase III trial for Truqap plus chemotherapy in advanced or metastatic triple-negative breast cancer

www.astrazeneca.com

Monday, Jun 17

Imfinzi plus chemotherapy approved in the US for mismatch repair deficient advanced or recurrent endometrial cancer

www.astrazeneca.com

Sunday, Jun 16

18

Calquence plus chemoimmunotherapy reduced the risk of disease progression or death by 27% vs. standard of care in patients with untreated mantle cell lymphoma in ECHO Phase III trial

www.astrazeneca.com

Wednesday, Jun 12

09

Farxiga approved in the US for the treatment of paediatric type-2 diabetes

www.astrazeneca.com

Monday, Jun 10

19

Tagrisso granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

www.astrazeneca.com

Wednesday, Jun 5

17

Acquisition of Fusion completed

www.astrazeneca.com

Monday, Jun 3

16

Tagrisso with the addition of chemotherapy recommended for approval in the EU by CHMP for patients with EGFR-mutated advanced lung cancer

www.astrazeneca.com

01

Tagrisso reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

www.astrazeneca.com

Sunday, Jun 2

16

Imfinzi is first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

www.astrazeneca.com

Enhertu demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

www.astrazeneca.com

Monday, May 27

13

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

www.astrazeneca.com

Saturday, May 25

17

Early chronic kidney disease intervention could save four European health systems up to €15.8 billion over 10 years

www.astrazeneca.com

Wednesday, May 22

18

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

www.astrazeneca.com

Tuesday, May 21

17

AstraZeneca sets ambition to deliver $80 billion Total Revenue by 2030 and sustained growth post 2030

www.astrazeneca.com

Monday, May 20

AstraZeneca plans $1.5 billion manufacturing facility for antibody drug conjugates (ADCs) in Singapore

www.astrazeneca.com

Thursday, May 16

15

SUPERNOVA Phase III trial of sipavibart long-acting antibody met primary endpoints in preventing COVID-19 in immunocompromised patient population

www.astrazeneca.com

Monday, May 6

18

AstraZeneca completes equity investment agreement with Cellectis

www.astrazeneca.com

Thursday, May 2

15

Calquence combination regimen demonstrated statistically significant and clinically meaningful improvement in progression-free survival in 1st-line mantle cell lymphoma in ECHO Phase III trial

www.astrazeneca.com

Wednesday, May 1

AstraZeneca unveils latest research across key respiratory and immune-mediated diseases at ATS 2024 showcasing strength of its broad pipeline and portfolio

www.astrazeneca.com

Monday, Apr 29

13

Truqap plus Faslodex recommended for approval in the EU by CHMP for patients with advanced ER-positive breast cancer

www.astrazeneca.com

Enhertu demonstrated statistically significant and clinically meaningful improvement in progression-free survival in HR-positive,

www.astrazeneca.com

Thursday, Apr 25

10

Q1 2024 results

www.astrazeneca.com

Tuesday, Apr 23

09

Voydeya approved in the EU as add-on treatment to ravulizumab or eculizumab for adults with the rare disease PNH who have residual haemolytic anaemia

www.astrazeneca.com

Wednesday, Apr 17

14

AstraZeneca advances the science of infectious disease protection at ECCMID 2024

www.astrazeneca.com

Tuesday, Apr 16

10

Imfinzi plus chemotherapy doubled overall survival rate at three years for patients with advanced biliary tract cancer in TOPAZ-1 Phase III trial

www.astrazeneca.com